NASDAQ NMS - GLOBAL MARKET · BCDA
-2.83% · -$0.0300 · Vol 101.9K
Market closed · last close 4:00 PM ET · price as of 17:35:25 ET
BioCardia Inc

BioCardia Inc

Biotechnology
$1.03
Card
Relationship Map

Follow $BCDA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $BCDA by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
BCDA
BioCardia Inc
Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

72/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is BCDA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BCDA catalysts
About BioCardia Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
1995
Employees
21
Country
US

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.06
Day high
$1.08
Day low
$1.02
Previous close
$1.06
52W high
$1.56
-33.97% from high
52W low
$0.7711
33% of range
Market cap
$15.7M
EPS
$-0.7997
Beta
-0.79
Shares out
15.1M
Volume
101.9K
0.36× rel vol
Avg volume
284.9K
VWAP
$1.05
Price history computed in-house
1W
-0.96%
1M
-4.63%
3M
+13.16%
1Y
-23.13%
YTD
-17.60%
SMA 50 $1.05 · below
SMA 200 $1.10 · below
52W position 33%

BCDA overview

Veridion Score
72
Registered · 2026-10-09
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around BCDA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading BCDA Form 4 filings
Public disclosures

Congress activity in BCDA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

BCDA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BCDA in this window.
Lobbying spend

BCDA lobbying filings, year to date.

Registered lobbying filings matched to BioCardia Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BCDA in this window.
Loading news for BCDA
Analyst ratings
Sovereign unlock shows live analyst consensus for BCDA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.